Rheumatology International最新文献

{"title":"COVID-19 is a trigger of autoimmune rheumatic diseases: a hypothesis tested over time.","authors":"Aisulu Karkabayeva, Khilola Mirakhmedova, Shoira Khusinova, Abdimutalib Mamasaidov, Chokan Baimukhamedov","doi":"10.1007/s00296-024-05766-3","DOIUrl":"10.1007/s00296-024-05766-3","url":null,"abstract":"<p><p>We discuss the paper recently published in Rheumatology Internationa. This article reflects on the prevalence of autoimmune rheumatic diseases (ARD) during the COVID-19 pandemic (2020-2023) and compares the same with the pre-pandemic period (2016-2019). We assume that SARS-CoV-2 triggers ARD. This study concerns the 10 million population of Greece, and this work convincingly confirms our hypothesis. Besides, four large cohort studies have demonstrated an increased incidence of autoimmune diseases after surviving COVID-19. Compared to the prepandemic period, all ARD increased, and RA growth in the index study reached a level of more than 20% during the pandemic. A similar trend was observed in our report covering four Central Asian republics, namely Kazakhstan, Kyrgyzstan, Uzbekistan, and Tajikistan. The alarming growth of ARDs due to the consequences of the pandemic can still be predicted for the coming years. Healthcare professionals worldwide should be aware of this hypothesis to plan their COVID-19, long COVID, and ARD diagnostic and therapeutic strategies. We agree with the authors of the index article that more resources and research studies are warranted to optimize the diagnosis and treatment of ARDs in this challenging time.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 1","pages":"11"},"PeriodicalIF":3.2,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring disease activity and treatment response in ankylosing spondylitis: a retrospective study of hematologic inflammatory markers.","authors":"Oznur Sadioglu Cagdas, Neslihan Gokcen, Ayten Yazici, Ayse Cefle","doi":"10.1007/s00296-024-05763-6","DOIUrl":"10.1007/s00296-024-05763-6","url":null,"abstract":"<p><strong>Background: </strong>Hematological markers such as the neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), and platelet-lymphocyte ratio (PLR) are reliable indicators of inflammation. This study aims to investigate the potential role of these markers in assessing disease activity and treatment response in biologic-naive Ankylosing Spondylitis (AS) patients following the initiation of biological agents.</p><p><strong>Materials and methods: </strong>We designed this study as a retrospective cohort study with data obtained from a single center. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and The Bath Ankylosing Spondylitis Functional Index (BASFI) were used to evaluate disease activity and functional status of AS patients. Laboratory results at baseline, 3rd, 6th, and 12th months were documented. We calculated hematologic inflammatory markers for each visit. Mean platelet volume (MPV) and red cell distribution width (RDW) were also noted.</p><p><strong>Results: </strong>54 biologic-naive patients with AS were included in this study. These inflammatory markers, except RDW, decreased over time. BASDAI, BASFI, CRP and ESR were significantly lower at 3rd, 6th, and 12th months compared to baseline values (all p < 0.001). Furthermore, NLR, PLR, and MLR showed a statistically significant decrease at 3rd, 6th, and 12th months compared to baseline values (all p < 0.001). However, when comparing the values at the 3rd, 6th, and 12th months, no statistically significant differences were observed. We also found no correlation between hematological inflammatory markers and BASDAI scores, despite observing some correlations between hematological markers and acute phase reactants.</p><p><strong>Conclusion: </strong>These markers could be valuable assessment tools for indicating disease activity and monitoring patients with AS after initiating biological treatment.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 1","pages":"10"},"PeriodicalIF":3.2,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceived effects of health status on sexual activity in patients with axial spondyloarthritis: a 5-year follow-up study.","authors":"Gudrun Rohde, Kari Hansen Berg, Are Hugo Pripp, Glenn Haugeberg","doi":"10.1007/s00296-024-05758-3","DOIUrl":"10.1007/s00296-024-05758-3","url":null,"abstract":"<p><p>Axial spondyloarthritis (ax-SpA) causes pain, fatigue, stiffness, loss of physical function, and poor health status, which can influence sexual activity and enjoyment. To explore whether patients with ax-SpA perceive that their health status effects their sexual activity and to identify predictors of these perceived effects on sexual activity after a 5-year follow-up. Data about demographics, disease, medication, health-related quality of life (HRQOL), and sexual quality of life (SQOL) were collected at the baseline and 5-year follow-up. The perceived effect of health status on sexual activity was measured by question 15 in the 15D questionnaire. Data were analysed using the McNemar and independent paired t tests and logistic regression. In the 244 patients with ax-SpA (30% women, 70% men; mean age, 46 years), measures reflecting disease activity decreased and comorbidities increased, and more patients were treated with biological drugs at 5 years. Compared with patients whose health status had little/no effect on sexual activity (n = 200), those who perceived that their health status had a large effect on sexual activity (n = 44) were older, exercised less, fewer were employed, had more comorbidities, higher disease activity, and lower HRQOL and SQOL. The baseline predictors of a negative effect of health status on sexual activity were old age and low SQOL. Patients reporting that their health status had a large effect on sexual activity at 5 years were older, had more disease activity, and lower HRQOL and SQOL.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 1","pages":"9"},"PeriodicalIF":3.2,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11682003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remission induction therapies and long-term outcomes in granulomatosis with polyangiitis and microscopic polyangiitis: real-world data from a European cohort.","authors":"Stefan Krämer, Kristian Vogt, Theresa Maria Schreibing, Martin Busch, Tobias Schmitt, Raoul Bergner, Sebastian Mosberger, Thomas Neumann, Thomas Rauen","doi":"10.1007/s00296-024-05757-4","DOIUrl":"10.1007/s00296-024-05757-4","url":null,"abstract":"<p><p>To explore disease characteristics, renal involvement and induction treatment strategies over the last decades and evaluate relapse rates and renal outcomes in ANCA-associated vasculitides (AAV). We retrospectively analyzed remission, relapse rates and the occurrence of the composite endpoint (comprising death and renal failure) in newly diagnosed AAV cases in four tertial referral centers in Germany and Switzerland diagnosed between 1999 and 2022. Hazard ratios were computed by Cox proportional hazard and Kaplan-Meier curves were plotted to compare therapeutic strategies after propensity-matching. In our cohort of 358 AAV patients, 203 (58.1%) were classified as granulomatosis with polyangiitis (GPA) based on the novel 2022 ACR/EULAR criteria, 139 (38.8%) as microscopic polyangiitis (MPA). The proportion of MPA cases among all AAV patients increased from 28.9% between 1999 and 2013 up to 46.7% thereafter. Cyclophosphamide (CYC) was chosen most frequently for remission induction (74.8% before 2013 and 57.3% thereafter), whereas the use of rituximab (RTX) increased from 5 to 26% within these periods. GPA patients had a higher relapse rate as compared to MPA patients (41.3% vs. 25.9%, p = 0.006). However, in AAV patients with renal involvement, renal events (i.e. end-stage kidney disease or a persistent drop in the estimated glomerular filtration rate (eGFR) below 15 ml/min/1.73 m²) occurred more frequently in MPA patients, particularly under RTX treatment as compared to matched CYC counterparts (11.8% vs. 7.5%, p = 0.011). In our cohort, GPA patients exhibited frequent relapses, advocating for a more intense and extended treatment. MPA patients had lower relapse rates, however, RTX was less effective to prevent renal endpoints in MPA as compared to CYC, highlighting the need to further investigate additional treatment strategies.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 1","pages":"7"},"PeriodicalIF":3.2,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142882910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discontinuation of biologic and target-specific therapy in patients with rheumatoid arthritis: a retrospective cohort study.","authors":"Stefka Neycheva, Emilia Naseva, Zguro Batalov, Rositsa Karalilova","doi":"10.1007/s00296-024-05752-9","DOIUrl":"10.1007/s00296-024-05752-9","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis is a progressive disease that requires continuous treatment. Despite the excellent results, treatment with biologics and target-specific disease-modifying anti-rheumatic drugs often has to be interrupted due to insufficient therapeutic effectiveness, toxicity, or side effects.</p><p><strong>Purpose: </strong>The purpose of this study is to identify the reasons and factors influencing treatment discontinuation with biologic and target-specific drugs among the Bulgarian patients with rheumatoid arthritis.</p><p><strong>Patients and methods: </strong>This is a single-centre, retrospective observational cohort study, that includes 154 patients with seropositive rheumatoid arthritis, who underwent a total of 221 therapeutic courses with biologic and target-specific drugs over a period of 12 years.</p><p><strong>Results: </strong>Out of the 221 therapeutic courses, 103 (46.6%) were discontinued. Due to an initial lack of efficacy, treatment was interrupted in 38 of cases (36.9%). A secondary lack of efficacy led to the discontinuation of 24 treatment regimens (23.3%). Allergic reactions and \"other\" reasons necessitated the cessation of therapy in 41 cases (39.8%). The male gender (HR = 2.111; 95%CI 1.261-3.535), age below 59 years (HR = 1.791, 95%CI 1.162-2.760), shorter disease duration (HR = 0.995, 95%CI 0.993-0.998), co-morbidity with diabetes mellitus (HR = 3.463, 95%CI 1.189-10.090), cerebrovascular disease (HR = 2.490, 95%CI 1.215-5.102), and the type of medication were identified as factors influencing the interruption of treatment. Age (p = 0.012), disease duration (р=0.06), and therapy duration (р<0.01) have a significant impact on the reasons for treatment discontinuation.</p><p><strong>Conclusions: </strong>Awareness of the reasons and factors influencing the discontinuation of treatment with biologic and target-specific drugs is crucial for improving existing therapeutic strategies and developing futures ones.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 1","pages":"6"},"PeriodicalIF":3.2,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of comorbidities and cardiovascular risk factor management in hand osteoarthritis: a cross-sectional study.","authors":"Sylvain Mathieu, Françoise Fayet, Marie-Hélène Salembien, Malory Rodere, Martin Soubrier, Anne Tournadre","doi":"10.1007/s00296-024-05764-5","DOIUrl":"10.1007/s00296-024-05764-5","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the prevalence of comorbidities and management of cardiovascular risk factors according to established guidelines for patients with hand osteoarthritis.</p><p><strong>Methods: </strong>A cross-sectional study was conducted that included 110 hand osteoarthritis patients. The clinical parameters (pain, function, grip strength, quality of life, sarcopenia, and comorbidities) were assessed along with cardiovascular (CV) risk factors (blood pressure, body mass index, and dyslipidaemia). CV risk was assessed using SCORE2 or SCORE2-OP algorithms. Comparisons of patient characteristics were performed using Student's or chi-squared tests.</p><p><strong>Results: </strong>Twenty-eight patients were identified with comorbidities, and they tended to be older, male, and with a lower quality of life. The median SCORE2 was 5.1%. SCORE2 was negatively associated with grip strength (r=-0.27, p = 0.02). There was no difference in SCORE2 between hand osteoarthritis patients with (n = 60) and without (n = 50) neuropathic-like pain (5.6 ± 3.7 versus 6.2 ± 3.3%; p = 0.38). Among the 40 patients with an intermediate or high CV risk, 33 (82.5%) were off target for low-density lipoproteins (LDL) level with no lipid-lowering treatment (n = 29) or an insufficient statin treatment (n = 4). Obesity was observed in 24 patients (21.8%) and 30 (27.3%) were overweight. Forty-two patients (41.2%) had blood hypertension (41 systolic and one diastolic patient) despite treatment for 9 patients.</p><p><strong>Conclusions: </strong>We found an increased CV risk in hand osteoarthritis patients who had an insufficient LDL cholesterol target achievement. Hand osteoarthritis patients appear to have a pro-atherogenic profile. These results suggest that CV risk factors should be assessed in patients with hand osteoarthritis and managed according to recommended guidelines.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 1","pages":"5"},"PeriodicalIF":3.2,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful rituximab treatment in a seronegative rheumatoid arthritis patient with concurrent cold agglutinin syndrome and immune thrombocytopenia.","authors":"Koji Suzuki, Mitsuhiro Akiyama, Hiroshi Takei, Yuko Kaneko","doi":"10.1007/s00296-024-05759-2","DOIUrl":"10.1007/s00296-024-05759-2","url":null,"abstract":"<p><p>Cold agglutinin disease, a subtype of cold-type autoimmune hemolytic anemia, is referred to as cold agglutinin syndrome (CAS) when it develops secondary to other conditions. Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by the peripheral destruction of platelets. While both CAS and ITP can occur in patients with rheumatoid arthritis (RA), their concurrent manifestation in a single patient has not been reported, leaving the optimal treatment strategy for such a complex case unclear. Given that rituximab has been reported to be effective in treating RA, CAS, and ITP, it may be a promising treatment option for cases where these three conditions co-occur. We present the first case of RA complicated by both CAS and ITP, where the patient achieved complete remission with rituximab therapy. Furthermore, our review of the literature identified three cases of CAS and three cases of ITP in RA patients, all successfully treated with rituximab. These findings highlight the potential efficacy of rituximab in managing this challenging and potentially life-threatening combination of autoimmune diseases.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 1","pages":"2"},"PeriodicalIF":3.2,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New onset heart failure in adolescents with inflammatory joint disease treated with TNF-α inhibitors: a case-based review.","authors":"Sophie Mavrogeni, Evdoxia Sapountzi, Kyveli Chiotopoulou, Lampros Fotis","doi":"10.1007/s00296-024-05750-x","DOIUrl":"10.1007/s00296-024-05750-x","url":null,"abstract":"<p><p>The safety of tumor necrosis factor (TNF) inhibitors has been demonstrated for over two decades. However, their effects on cardiovascular function in patients with rheumatic diseases remain controversial, and conclusions are additionally hampered by the cardiovascular complications inherent in such diseases. We present two 15-year-old patients diagnosed with ankylosing spondylitis and juvenile idiopathic arthritis classified as polyarthritis with positive rheumatoid factor, respectively. Soon after treatment onset with adalimumab and etanercept, respectively, they developed myocardial inflammation leading to heart failure. Their condition improved upon treatment discontinuation and onset of secukinumab and tocilizumab, respectively. A thorough literature search revealed that these are the only cases of heart failure reported to date after anti-TNF treatment in adolescents with rheumatic diseases. Although cardiovascular adverse effects seem to be very rare in this population, even atypical symptoms of cardiac failure should not be ignored, and cardiac function should be closely monitored when administering anti-TNF-α.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 1","pages":"4"},"PeriodicalIF":3.2,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary involvement in newly diagnosed and untreated rheumatoid arthritis and psoriatic arthritis: a prospective longitudinal study.","authors":"Lone Winter, Simon M Petzinna, Dirk Skowasch, Carmen Pizarro, Marcel Weber, Daniel Kütting, Charlotte Behning, Claus-Jürgen Bauer, Valentin S Schäfer","doi":"10.1007/s00296-024-05751-w","DOIUrl":"10.1007/s00296-024-05751-w","url":null,"abstract":"<p><strong>Objectives: </strong>To longitudinally assesses pulmonary involvement in newly diagnosed rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients over a 12-months follow-up. To identify biomarkers and establish a diagnostic algorithm for monitoring pulmonary changes.</p><p><strong>Methods: </strong>Newly diagnosed RA and PsA patients were examined with clinical and laboratory assessments, pulmonary function tests (PFT), and chest radiography (CXR) at three-months intervals for one year.</p><p><strong>Results: </strong>The study enrolled 50 patients (26 RA, 24 PsA) and 26 controls. At baseline, 37.0% of arthritis patients (50.0% RA, 22.7% PsA) exhibited radiographic pulmonary involvement, with 64.7% being asymptomatic. No association was observed between CXR and PFTs. Reduced pathological breathing width was noted in 64.0% of patients (RA 69.2%, PsA 58.3%) and 23.1% of controls (p < .001). Thoracic excursion and lung auscultation showed no differences. During follow-up, PFT and physical examination findings remained stable. Mean CRP levels significantly decreased in RA patients from 23.5 mg/l (± 33.6; 95% CI: 9.9-37.1) to 2.7 mg/L (± 3.4; 95% CI: 1.0-4.3), and in PsA patients from 13.3 mg/L (± 18.0; 95% CI: 5.7-20.9) to 8.1 mg/L (± 16.2; 95% CI: 0.1-16.2) (p < .001). Additionally, significant reductions in disease activity scores and improvements in six-minute walking distance were observed (p < .001). No associations were identified between PFT outcomes, disease activity, or rheumatological medications throughout the disease course.</p><p><strong>Conclusion: </strong>Our study underscores the prevalence of significant, predominantly asymptomatic pulmonary involvement in newly diagnosed RA and PsA patients. The lack of correlation between pulmonary function, disease activity, and medication during disease progression suggests that reducing arthritic disease activity does not necessarily mitigate the risk or severity of pulmonary involvement. Finally, our finding underscore the need for more sensitive biomarkers and optimized monitoring strategies.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 1","pages":"3"},"PeriodicalIF":3.2,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Joint swelling in the hand in rheumatoid arthritis: agreement between clinical evaluation, ultrasonography, magnetic resonance imaging and patient self-evaluation.","authors":"Lau Brix, Agnete Hedemann-Nielsen, Lise Medrud, Ulrich Fredberg, Torkell Ellingsen","doi":"10.1007/s00296-024-05762-7","DOIUrl":"10.1007/s00296-024-05762-7","url":null,"abstract":"<p><strong>Objective: </strong>To describe agreement in detection of joint swelling as the mandatory key of the diagnostic algorithm used in rheumatoid arthritis (RA). This was done by comparing clinical examinations, ultrasonography (US), Magnetic Resonance Imaging (MRI) and patient self-evaluation of the joints in the wrist and fingers (metacarpophalangeal joints (MCP) and proximal interphalangeal joints (PIP)) in an early untreated RA cohort.</p><p><strong>Methods: </strong>14 patients (8 women and 6 men, mean age ± standard deviation: 54.9 ± 14.5 years, range: 34-81 years) with symptom duration of less than six months, steroid and DMARD naïve at the time of examination and no previous history of arthritis were included in the study. US techniques included B mode and Color Doppler while MRI included a variety of imaging sequences (STIR, T1W TSE and T1W VIBE).</p><p><strong>Results: </strong>Overall, there was good agreement between clinical evaluation, evaluation by US, by MRI or patients' own evaluation of joint swelling. Patient self-evaluation converged with the clinical evaluation in 12 cases (86%).</p><p><strong>Conclusion: </strong>Agreement was good among the applied imaging modalities and patient self-evaluation when compared to the clinical evaluations. Adding MRI to the US examination did not provide further diagnostic information.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 1","pages":"1"},"PeriodicalIF":3.2,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}